miDiagnostics
Private Company
Funding information not available
Overview
miDiagnostics is a private, commercial-stage diagnostics company leveraging a disruptive silicon chip platform to deliver rapid, accurate, and low-cost molecular tests. Its integrated system consists of a single-use test card embedded with the chip, a portable reader, and supporting software, targeting a wide menu of syndromic conditions. With recent FDA clearance for an HSV-1&2 test and a focus on moving testing closer to the patient, the company is positioned to transform traditional lab-based diagnostics into rapid point-of-care solutions.
Technology Platform
Proprietary silicon chip-based nanofluidic processor enabling passive liquid handling and ultra-fast PCR, integrated into a single-use test card, portable reader, and software system for sample-to-answer molecular diagnostics in under 30 minutes.
Opportunities
Risk Factors
Competitive Landscape
miDiagnostics competes in the crowded point-of-care molecular diagnostics market against large, established players like Abbott, Roche, Cepheid, and BioFire. Its differentiation hinges on the unique silicon chip technology promising superior speed (under 30 minutes) and low cost at lab-quality accuracy, but it must overcome significant barriers to market adoption and scale.